ELI LILLY & Co (LLY)
- Sector
- Health Care
- Industry
- Pharmaceuticals
- Last price
- $1208.74
- As of
Kresmion compiles this page from LLY's SEC filings, its 13F institutional holders and the market events Kresmion detects, each linked to its source.
ELI LILLY & Co (LLY): 8 institutional managers tracked by Kresmion reported non-option positions in their 2026Q2 Form 13F filings, and the most recent SEC filing on record for the company is a Form 10-Q filed 2026-08-05.
See the full LLY dossier
Price with insider and filing markers, who is positioning, fundamentals and peers for LLY on one page. Preview it with sample data, then open it live with a free account.
Preview the LLY dossierActive signals for LLY
- highCONSENSUS_BUY
3 tracked funds increased LLY this 2026Q2, institutional consensus
- highINSTITUTIONAL_EXIT
CITADEL ADVISORS LLC cut 55% of LLY (2026Q2)
- highINSTITUTIONAL_SURGE
Point72 Asset Management, L.P. added +125% to LLY (2026Q2)
- highINSTITUTIONAL_EXIT
Point72 Asset Management, L.P. cut 51% of LLY (2026Q2)
- highINSTITUTIONAL_SURGE
MILLENNIUM MANAGEMENT LLC added +246% to LLY (2026Q2)
FREE, NO ACCOUNT
Every signal on LLY, as it fires
You are seeing 5 of 79 signals recorded on LLY since 2026-05-02.
The five above landed across 2 days. The other 74 were recorded on 27 other days.
No fixed schedule: it goes out when the data has something in it. Unsubscribe anytime. We never sell your data.
Largest reported share positions in LLY (2026Q2)
| Manager / security | Market value | % portfolio | QoQ |
|---|---|---|---|
| CITADEL ADVISORS LLCCUSIP 532457108 · 2026Q2 | $1.13B | 0.13% | , |
| D. E. Shaw & Co., Inc.CUSIP 532457108 · 2026Q2 | $595.6M | 0.28% | , |
| MILLENNIUM MANAGEMENT LLCCUSIP 532457108 · 2026Q2 | $219.1M | 0.08% | , |
| Bridgewater Associates, LPCUSIP 532457108 · 2026Q2 | $104.4M | 0.43% | , |
| TWO SIGMA INVESTMENTS, LPCUSIP 532457108 · 2026Q2 | $97.4M | 0.07% | , |
| RENAISSANCE TECHNOLOGIES LLCCUSIP 532457108 · 2026Q2 | $31.3M | 0.04% | , |
| SOROS FUND MANAGEMENT LLCCUSIP 532457108 · 2026Q2 | $26.6M | 0.33% | , |
| Point72 Asset Management, L.P.CUSIP 532457108 · 2026Q2 | $12.6M | 0.01% | , |
Quarterly SEC Form 13F disclosures from the managers Kresmion tracks, not a complete ownership ranking. Non-option holdings only; reported put and call positions are excluded. Different securities are labeled by CUSIP. Values are reporting-period snapshots, not current position values. Filings can arrive up to 45 days after quarter-end.
Recent SEC filings, LLY
- 10-QSEC EDGAR ↗
- 8-KSEC EDGAR ↗
- 8-KSEC EDGAR ↗
- 8-KSEC EDGAR ↗
- 10-QSEC EDGAR ↗
- 8-KSEC EDGAR ↗
- 10-KSEC EDGAR ↗
- 8-KSEC EDGAR ↗
- 8-KSEC EDGAR ↗
- 8-KSEC EDGAR ↗
LLY against its peers
LLY's net margin of 31.7% ranks in the 93rd percentile of 22 Pharmaceuticals sub-industry peers, fiscal periods ending between 2025-12-28 and 2025-12-31.
| Metric | LLY | Peer median | Percentile | n |
|---|---|---|---|---|
| Revenue FY | 65.2B USD | 6.2B USD | 93 | 21 |
| Gross margin | n/a | 70.1% | n/a | 10 |
| Operating margin | n/a | 10.5% | n/a | 16 |
| Net margin | 31.7% | 10.3% | 93 | 22 |
| Return on equity | 77.8% | 15.4% | 94 | 23 |
| P / E | 52.7x | 20.2x | 79 | 11 |
| 1 year | 48.8% | 28.7% | 70 | 24 |
Peers (25): JNJ, MRK, NVS, AZN, NVO, PFE, BMY, GSK, TEVA, ZTS, VTRS, JAZZ, CORT, AXSM, AMRX, OGN, AMLX, TARS, SUPN, LQDA, HRMY, BHC, XERS, TRVI, GPCR. Fiscal periods ending between 2025-12-28 and 2025-12-31. Every figure is one full fiscal year read from one annual filing (LLY: 10-K), reported in USD. Nothing is trailing twelve months and nothing is converted between currencies. Source: SEC EDGAR XBRL company facts (public domain); prices from Kresmion's daily equity market-data snapshot. Open the full comparison.
Related tickers
Follow LLY on a live board
Kresmion is a cross-asset market-intelligence terminal. Open a board scoped to LLY for its filings, 13F changes, insider trades, options positioning, and confluence read in one view, each with its source.